Is It Too Late to Buy BioNTech Stock?

If you're considering an investment in the newly famous coronavirus vaccine developer BioNTech, (NASDAQ: BNTX) you're right to wonder if the window of opportunity is still open. Based on the expected level of demand in 2022, jab sales may peak before the end of this year, and a widening field of competitors could soon start to contest the company's market share.

On the other hand, BioNTech's decline is far from guaranteed, and it's being supported by a handful of different trends, not to mention probable future developments. Let's analyze some of the arguments in favor of and against it being too late to invest in the stock in September to get a clearer view.

Image source: Getty Images

Source Fool.com